GPEx® Lightning: Accelerating Stable Cell Line Development For Complex Biologics

If you're developing multispecific antibodies or other complex biologics, stable cell line development is probably already on your critical path. GPEx® Lightning is designed specifically to get it off that path. Stable cell pools in 25 days, titers above 15g/L for traditional monoclonal antibodies (mAbs) and exceeding 11g/L for bispecifics — those aren't aspirational numbers, they're the platform's published performance benchmarks.

What makes this possible is the underlying architecture. GPEx® Lightning uses 100-plus dock sites located in transcriptionally active chromatin regions, with recombinase-mediated, dock-directed gene insertion. That means consistent, predictable expression rather than the positional variability you get with random integration. The glutamine synthetase (GS) selection system requires no antibiotics and no dual selection, which simplifies your workflow and reduces failure points.

For teams working across modalities, the tunable, balanced expression system handles multigene constructs and difficult-to-express molecules without requiring molecule-specific re-optimization. Scalability runs from Ambr250 through GMP bioreactors, and stability holds beyond 60 generations.

For emerging or small biopharma especially, compressing timelines by 6–12 weeks is meaningful. Contact Catalent to discuss how GPEx® Lightning fits your specific program.